Related Experiment Video
Updated: Jun 26, 2026

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area
Published on: August 10, 2012
Neuroimaging of L-dopamine and dopamine agonist therapy - revisited
1Human Brain Research Center, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto 606-8507, Japan. fukuyama@kuhp.kyoto-u.ac.jp
Abstract:
Treatment of Parkinson's disease (PD) is improving and we can choose a variety of drugs and surgical procedures for appropriate stages of the disease. However, we depend upon clinical signs and symptoms as well as patient reports to evaluate such issues. While neurochemical research into the etiological aspects of PD has been expanding, imaging is still under investigation. Here, I summarize the results of studies with regard to imaging of dopaminergic systems, and discuss the key points for imaging of PD with respect to treatment evaluation.
More Related Videos
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Drugs Affecting Neurotransmitter Synthesis
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Parkinson Disease ll: Pathophysiology
Parkinson's Disease: Overview
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...

